干扰素、拉米夫定抗乙肝病毒复制随访6个月-1年疗效的Meta分析

Meta-analysis of follow-up six month and one year efficacy chronic hepatitis B with INF and LAM

目的分析干扰素和拉米夫定抗乙型肝炎病毒复制的近远期效果。方法对干扰素治疗的14项及拉米夫定治疗的5项文献研究的血清学指标,应用MeTa分析进行同质性检验和合并效应量估计。结果干扰素和拉米夫定组血清学指标改变的同质性检验P均大于0.05,具有同质性,选用固定效应模式合并结果。ALT复常、HBeAg阴转、HBV-DNA阴转95%可信区间:干扰素组分别为1.13-2.79、0.96-1.61、1.11-1.88;拉米夫定组分别为0.84-2.56、0.62-1.84、1.01-2.98。结论干扰素、拉米夫定治疗后随访6个月-1年结果,HBV-DNA的阴转效果均比治疗结束时有所下降,HBeAg的阴转效果无明显变化。

Objective To analyze the efficacy of interfereon（INF） and lamivudine（IAM） with chronic hepatitis B. Methods 14 articles about INF and 5 articles about IAM were taken the test for homogeneity and srummary statistic. Results The fixed effect model was chose as the text for homogeneity P 〉0.05. ALT, HBeAg and HBV- DNA normalization 95 % confidence interval（95 % CI） was 1.13 - 2.79, 0.96 -1.61, 1.11 - 1.88 respectively in group INF and 0.84 -2.56,0.62- 1.84,101 -2.98 respectively in group IAM. Conclusion HBV- DNA normalization rate at the end of treatment is lower than that at the end of follow- up with INF and IAM. But HBeAg is no variety.